Effect of selenium supplementation in the treatment of women with polycystic ovary syndrome candidate for IVF.

Clinical trial of the effect of selenium supplementation compared with the placebo on gene expression related to inflammation in women with polycystic ovary syndrome candidate for IVF.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170513033941N23

Enrollment

Registered

2017-12-20

Start date

2017-12-11

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: Selenium supplements (Nature, California, USA), 200 µg, daily, for 8 weeks orally. Intervention 2: Control group: Placebo (Barij Essence, Kashan, Iran), daily, for

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with polycystic ovary syndrome. Individuals aged 18 to 40 years.

Exclusion criteria

Exclusion criteria: Exclusion criteria: Metabolic abnormalities such as diabetes, impaired glucose tolerance and thyroid dysfunction

Design outcomes

Primary

Measure	Time frame
Expressed levels of TNF-a gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.	—

Secondary

Measure	Time frame
Expressed levels of IL-1 gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of IL-8 gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of VEGF. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of TGF-B. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.	—

Measure

Time frame

Expressed levels of IL-1 gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of IL-8 gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of VEGF. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of TGF-B. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 3, 2026